Quarterly ResultMay 13, 2026, 04:23 PM
Sunshine Biopharma Q1 Sales Down 9.1%; Net Loss Widens to $1.24M
AI Summary
Sunshine Biopharma Inc. reported a Q1 2026 net loss of $1.24 million, widening from $1.18 million in Q1 2025, with sales decreasing by 9.1% to $8.09 million. The company is engaged in a legal dispute over a $5.3 million earnout with a former subsidiary president. Despite financial challenges, the company is advancing its K1.1 mRNA liver cancer drug, which showed positive initial results in animal testing, and plans to launch 12 new generic drugs in 2026.
Key Highlights
- Q1 2026 net loss widened to $1.24 million from $1.18 million in Q1 2025.
- Q1 2026 sales decreased 9.1% to $8.09 million from $8.90 million year-over-year.
- Basic loss per share improved to $(0.25) in Q1 2026 from $(0.44) in Q1 2025.
- Cash and cash equivalents were $6.91 million as of March 31, 2026.
- Company disputes a $5.3 million legal claim from former Nora Pharma president.
- K1.1 mRNA liver cancer drug showed positive tumor reduction in animal tests.
- 12 new generic drugs are anticipated for launch in Canada during 2026.